Completed PHASE2 INTERVENTIONAL 4-arm NCT00399906

A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Three Different Doses of BMS-582949 Given Orally to Subjects With Moderate to Severe Plaque Psoriasis

Sponsor: Bristol-Myers Squibb

Conditions Psoriasis

Interventions BMS-582949 Placebo

Updated 8 times since 2017 Last updated: Nov 6, 2015 Started: Aug 31, 2007 Primary completion: Jan 31, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Psoriasis and is currently completed. Bristol-Myers Squibb leads this study, which shows 8 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Calgary, Canada , Carlton, Australia , Df, Mexico , Edmonton, Canada , Greenslopes, Australia , Halifax, Canada , Kogarah, Australia , Malvern, Australia , Monterrey, Mexico , Montreal, Canada and 11 more locations